Celularity (CELU) Income from Continuing Operations (2019 - 2025)
Celularity (CELU) posted quarterly Income from Continuing Operations of 24359000.0 for Q4 2025, down 83.26% year-over-year from 145519023.82 in Q4 2024, and down 5.56% quarter-over-quarter from 23076000.0 in Q3 2025.
Celularity (CELU) Income from Continuing Operations (2019 - 2025) Analysis & Trends
Celularity (CELU) has reported Income from Continuing Operations for 7 consecutive years, with 24359000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Income from Continuing Operations fell 83.26% year-over-year to 24359000.0; the TTM figure through Dec 2025 stood at 91713000.0 (down 58.42% YoY), while the FY2025 annual figure was 91716000.0, down 58.43% from the prior year.
- Income from Continuing Operations slipped to 24359000.0 in Q4 2025 per CELU's latest filing, from 23076000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 49938000.0 in Q3 2021 and bottomed at 93876000.0 in Q3 2023.
- Historically, Income from Continuing Operations has averaged 21591250.0 across 5 years, with a median of 20883500.0 in 2024.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations jumped 704.8% — and 2023, when it tumbled 2056.16%.
- Celularity's Income from Continuing Operations stood at 4040000.0 in 2021, then surged by 704.8% to 24434000.0 in 2022, then tumbled by 60.93% to 9547000.0 in 2023, then plunged by 239.23% to 13292000.0 in 2024, then plunged by 83.26% to 24359000.0 in 2025.
- Business Quant data shows CELU's Income from Continuing Operations at 24359000.0 in Q4 2025, 23076000.0 in Q3 2025, and 24524000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Celularity | 20.99 Mn | 14.82 Mn | -3.27 Mn | -24.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -24.36 Mn |
| Sep 30, 2025 | -23.08 Mn |
| Jun 30, 2025 | -24.52 Mn |
| Mar 31, 2025 | -19.75 Mn |
| Dec 31, 2024 | -13.29 Mn |
| Sep 30, 2024 | -16.10 Mn |
| Jun 30, 2024 | -6.49 Mn |
| Mar 31, 2024 | -22.01 Mn |
| Dec 31, 2023 | 9.55 Mn |
| Sep 30, 2023 | -93.88 Mn |
| Jun 30, 2023 | -47.95 Mn |
| Mar 31, 2023 | -64.02 Mn |
| Dec 31, 2022 | 24.43 Mn |
| Sep 30, 2022 | 4.80 Mn |
| Jun 30, 2022 | 47.83 Mn |
| Mar 31, 2022 | -62.87 Mn |
| Dec 31, 2021 | -4.04 Mn |
| Sep 30, 2021 | 49.94 Mn |
| Jun 30, 2021 | -64.52 Mn |
| Mar 31, 2021 | -81.50 Mn |